市場調查報告書
商品編碼
1359574
心內膜心肌切片市場規模 - 按產品(鑷子、配件)、按尖端(大彎、直、預彎)、最終用途和 - 到 2032 年的全球預測Endomyocardial Biopsy Market Size - By Product (Forceps, Accessories), By Tip (Maxi-curved, Straight, Pre-curved), By End-use & - Global Forecast to 2032 |
由於心臟相關疾病(包括心肌病變和心臟移植監測)的盛行率上升,以及對診斷和監測工具的更高需求,預計2023 年至2032 年心內膜心肌活體組織切片市場規模將以6.8% 的年複合成長率擴大。
最近,患者越來越意識到心臟評估(包括心內膜心肌切片)的重要性。醫生也認知到早期檢測和精確監測心臟病的價值,進一步推動了心內膜心肌活體組織切片的推薦和處方。此外,獨立的臨床實驗室平台正在增強其診斷測試能力和服務以支持市場發展。舉個例子,2023年9月,大型獨立臨床實驗室公司艾迪康控股有限公司開始提供中國領先的精準腫瘤公司Guardant Health的液體活體組織切片測試,以加速創新癌症療法的臨床研發。
整個心內膜心肌切片市場按產品、尖端、最終用途和地區進行細分。
根據產品,配件領域的產業價值預計在 2023 年至 2032 年間獲得顯著成長。心內膜心肌活體組織切片手術嚴重依賴專用配件,如活體組織切片鉗、導管和針頭。心血管疾病發生率的增加推動了對這些關鍵工具的持續需求,進一步需要準確的診斷和監測。活體組織切片配件的技術進步,例如改進設計和材料以提高安全性和精度也將刺激該細分市場的成長。
就最終用途而言,門診手術中心(ASC) 細分市場將在2022 年為心內膜心肌活體組織切片行業帶來可觀的收入,預計到2032 年將出現大幅成長。這是由於人們越來越偏愛心臟手術,包括心內膜心肌活體組織切片。ASC 具有成本效益、便利性和患者住院時間較短等特點。由於對提供門診護理的日益關注,心內膜心肌活體組織切片微創技術的不斷進步將有助於該領域的擴張。
由於心血管疾病盛行率上升(主要在印度和中國),亞太地區心內膜心肌切片市場預計在 2023 年至 2032 年間將出現強勁成長。意識的提高、醫療保健基礎設施的改善以及先進診斷程序的普及正在推動對心內膜心肌活體組織切片的需求。據估計,到2060年,亞洲65歲及以上的人口將超過12億人。該地區不斷成長的老年人口可能會導致心臟評估和監測需求的增加,從而進一步推動該地區行業的成長。
Endomyocardial Biopsy Market size is anticipated to expand at 6.8% CAGR from 2023 to 2032 driven by the rising prevalence of heart-related conditions, including cardiomyopathies and heart transplant monitoring coupled with the higher need for diagnostic and monitoring tools.
Lately, patients have grown increasingly aware about the significance of cardiac assessments, including endomyocardial biopsies. Physicians are also recognizing the value of early detection and precise monitoring of heart conditions, further fueling the recommendation and prescription of endomyocardial biopsies. Moreover, independent clinical laboratory platforms are increasing their diagnostic testing capabilities and services to support the market development. To cite an instance, in September 2023, Adicon Holdings Limited, a major independent clinical laboratory firm, started providing liquid biopsy tests from Guardant Health, a leading precision oncology company, in China to accelerate clinical R&D of innovative cancer therapeutics.
The overall endomyocardial biopsy market is segmented in terms of product, tip, end-use, and region.
Based on product, the industry value from the accessories segment is poised to gain significant traction between 2023 and 2032. Endomyocardial biopsy procedures rely heavily on specialized accessories, such as biopsy forceps, catheters, and needles. The continuous demand for these critical tools is driven by the increasing incidence of cardiovascular diseases, further necessitating accurate diagnosis and monitoring. Technological advancements in biopsy accessories, such as improved design and materials for enhanced safety and precision will also stimulate the segment growth.
In terms of end-use, the ambulatory surgical centers (ASCs) segment generated considerable revenue in the endomyocardial biopsy industry in 2022 and is projected to witness substantial growth through 2032. This is owing to the increasing preference for cardiac procedures, including endomyocardial biopsies at ASCs due to their cost-effectiveness, convenience, and shorter patient stays. The rising advancements in minimally invasive techniques for endomyocardial biopsies driven by the surging focus on providing outpatient care will contribute to the segment expansion.
Asia Pacific endomyocardial biopsy market is slated to record robust growth between 2023 and 2032 attributed to the rising prevalence of cardiovascular diseases, mainly in India and China. Increasing awareness, improved healthcare infrastructure, and greater access to advanced diagnostic procedures are driving the demand for endomyocardial biopsies. It has been estimated that by 2060, there will be more than 1.2 billion Asians aged 65 years and above. This growing geriatric population in the region may contribute to the increased need for cardiac assessment and monitoring, further propelling the regional industry growth.